 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Veracyte, Inc. Nasdaq: VCYT announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier GSC, a novel genomic test, in helping to improve lung cancer diagnosis. The data, based on widely accepted community guidelines for establishing analytical validity, add to the growing body of clinical evidence supporting the use of the Percepta GSC to guide next steps for patients with 